Jessie Raju

TL;DR: Testosterone replacement therapy with long-acting Testosterone Undecanoate significantly improved all domains of the IIEF and patient reported quality of life at 30 weeks and more significantly after 52-week open-label extension.

TL;DR: Testosterone replacement therapy significantly improved HbA1c, total cholesterol, and waist circumference in men with type 2 diabetes and therapeutic responses were related to achieving adequate serum testosterone levels.

TL;DR: This is the first double‐blind placebo‐controlled study conducted exclusively in a male type 2 diabetes population to assess the metabolic changes with testosterone replacement and indicates a threshold at which symptoms improve with physiological replacement.

TL;DR: It appears that baseline and changes in lipid values post fibrate treatment were not associated with change in LFT, with the greatest benefit seen in patients with higher baseline LFT values.

TL;DR: The results may explain the discrepancies observed in some randomized controlled trials whereby subgroup analysis of patients with the metabolic syndrome appeared to show benefit whereas this was absent in the total cohort, and future interventional studies using fibrates should perhaps focus on patients with low HDL-C levels.